0 Ask Beta Account

Rifampicin and breakfast

Gill GV

Lancet (London, England), 2(7995), 1135

DOI 10.1016/s0140-6736(76)92160-8 Source

Abstract

No abstract available for this article.

Topics

General OB/GYN > Pharmacology > Drug InteractionsResearch Methodology > Pharmacokinetics > Bioavailability
rifampicin breakfast food drug interaction, antibiotic absorption meal timing, drug absorption food interaction, rifampicin bioavailability gastric absorption, tuberculosis medication food interaction, Gill rifampicin pharmacokinetics, medication timing recommendations absorption, clinical pharmacology drug administration
DOI 10.1016/s0140-6736(76)92160-8 10.1016/s0140-6736(76)92160-8

Cite this article

Gill GV (1976). Rifampicin and breakfast. *Lancet (London, England)*, *2*(7995), 1135. https://doi.org/10.1016/s0140-6736(76)91108-9

Keywords

Rifampin

Related articles

Disease burden attributable to intimate partner violence against females and sexual violence against children in 204 countries and territories, 1990-2023: a systematic analysis for the Global Burden of Disease Study 2023
GBD 2023 Intimate Partner Violence and Sexual Violence against Children Collaborators, 2026 Lancet (London, England)

BACKGROUND: Violence against women and against children are human rights violations with lasting harms to survivors and societies at large. Intimate partner violence (IPV) and sexual violence against ...

General OB/GYNEthics/Philosophy

Burden of 375 diseases and injuries, risk-attributable burden of 88 risk factors, and healthy life expectancy in 204 countries and territories, including 660 subnational locations, 1990-2023: a systematic analysis for the Global Burden of Disease Study 2023
GBD 2023 Disease and Injury and Risk Factor Collaborators, 2025 Lancet (London, England)

BACKGROUND: For more than three decades, the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) has provided a framework to quantify health loss due to diseases, injuries, and associate...

Research MethodologyGeneral OB/GYN

Cervical cancer and hormonal contraceptives: collaborative reanalysis of individual data for 16,573 women with cervical cancer and 35,509 women without cervical cancer from 24 epidemiological studies
International Collaboration of Epidemiological Studies of Cervical Cancer et al., 2007 Lancet (London, England)

Background: Combined oral contraceptives are classified by the International Agency for Research on Cancer as a cause of cervical cancer. As the incidence of cervical cancer increases with age, the pu...

Contraception/Comparison > Adverse Effects > Cervical Cancer RiskGeneral OB/GYN > Gynecologic Oncology > Cervical Cancer EpidemiologyResearch Methodology > Study Design > Pooled Individual Data Reanalysis